ANRIL in Cardiovascular Diseases: Expression, Mechanism and Therapeutic Implications.

IF 3.1 3区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Cardiovascular Drugs and Therapy Pub Date : 2026-05-02 DOI:10.1007/s10557-026-07884-5

Hao Yang, Ying Li, Qiushuang Cai, Huimin Hua, Xia Liu, Yifei Liu, Wei Qin, Renfang Mao

{"title":"ANRIL in Cardiovascular Diseases: Expression, Mechanism and Therapeutic Implications.","authors":"Hao Yang, Ying Li, Qiushuang Cai, Huimin Hua, Xia Liu, Yifei Liu, Wei Qin, Renfang Mao","doi":"10.1007/s10557-026-07884-5","DOIUrl":null,"url":null,"abstract":"<p><p>Cardiovascular diseases (CVDs) remain a leading cause of global mortality, with pathogenesis driven by multifactorial processes including genetic susceptibility, metabolic dysregulation, angiogenesis, and inflammation. Long non-coding RNAs (lncRNAs) have been recognized as key modulators of gene expression in cardiovascular pathophysiology. Among them, the Antisense Non-coding RNA in the INK4 Locus (ANRIL)-mapping to the well-established CVD-associated chromosome 9p21 locus-has garnered substantial research interest. Initially identified in melanoma, ANRIL spans approximately 126.3 kb and comprises 19 exons, existing in both linear and circular isoforms with distinct functional profiles. This review systematically outlines the dysregulation of ANRIL expression across seven major cardiovascular conditions and elucidates the isoform-specific mechanisms through which it contributes to disease progression, integrating recent advances in this field. We further discuss emerging evidence suggesting a potential role of ANRIL in cardiac hypertrophy. In light of its involvement in diverse cardiovascular disorders, ANRIL represents a compelling candidate for therapeutic target and a promising biomarker, warranting further translational investigation.</p>","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2026-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular Drugs and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10557-026-07884-5","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Cardiovascular diseases (CVDs) remain a leading cause of global mortality, with pathogenesis driven by multifactorial processes including genetic susceptibility, metabolic dysregulation, angiogenesis, and inflammation. Long non-coding RNAs (lncRNAs) have been recognized as key modulators of gene expression in cardiovascular pathophysiology. Among them, the Antisense Non-coding RNA in the INK4 Locus (ANRIL)-mapping to the well-established CVD-associated chromosome 9p21 locus-has garnered substantial research interest. Initially identified in melanoma, ANRIL spans approximately 126.3 kb and comprises 19 exons, existing in both linear and circular isoforms with distinct functional profiles. This review systematically outlines the dysregulation of ANRIL expression across seven major cardiovascular conditions and elucidates the isoform-specific mechanisms through which it contributes to disease progression, integrating recent advances in this field. We further discuss emerging evidence suggesting a potential role of ANRIL in cardiac hypertrophy. In light of its involvement in diverse cardiovascular disorders, ANRIL represents a compelling candidate for therapeutic target and a promising biomarker, warranting further translational investigation.

查看原文本刊更多论文

ANRIL在心血管疾病中的表达、机制及治疗意义

心血管疾病（cvd）仍然是全球死亡的主要原因，其发病机制由多因素过程驱动，包括遗传易感性、代谢失调、血管生成和炎症。长链非编码rna （lncRNAs）已被认为是心血管病理生理中基因表达的关键调节因子。其中，INK4位点（ANRIL）上的反义非编码RNA （Antisense Non-coding RNA， ANRIL定位于已建立的cvd相关染色体9p21位点）引起了大量的研究兴趣。ANRIL最初在黑色素瘤中被发现，长度约为126.3 kb，由19个外显子组成，存在于线性和圆形异构体中，具有不同的功能谱。本综述系统地概述了七种主要心血管疾病中ANRIL表达的失调，并阐明了其促进疾病进展的同型特异性机制，整合了该领域的最新进展。我们进一步讨论新出现的证据表明ANRIL在心脏肥厚中的潜在作用。鉴于其参与多种心血管疾病，ANRIL代表了一个令人信服的候选治疗靶点和有前途的生物标志物，值得进一步的转化研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cardiovascular Drugs and Therapy 医学-心血管系统

CiteScore

8.30

自引率

0.00%

发文量

110

审稿时长

4.5 months

期刊介绍： Designed to objectively cover the process of bench to bedside development of cardiovascular drug, device and cell therapy, and to bring you the information you need most in a timely and useful format, Cardiovascular Drugs and Therapy takes a fresh and energetic look at advances in this dynamic field. Homing in on the most exciting work being done on new therapeutic agents, Cardiovascular Drugs and Therapy focusses on developments in atherosclerosis, hyperlipidemia, diabetes, ischemic syndromes and arrhythmias. The Journal is an authoritative source of current and relevant information that is indispensable for basic and clinical investigators aiming for novel, breakthrough research as well as for cardiologists seeking to best serve their patients. Providing you with a single, concise reference tool acknowledged to be among the finest in the world, Cardiovascular Drugs and Therapy is listed in Web of Science and PubMed/Medline among other abstracting and indexing services. The regular articles and frequent special topical issues equip you with an up-to-date source defined by the need for accurate information on an ever-evolving field. Cardiovascular Drugs and Therapy is a careful and accurate guide through the maze of new products and therapies which furnishes you with the details on cardiovascular pharmacology that you will refer to time and time again.